Glycopyrronium (PT001) vs Tiotropium bromide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

Glycopyrronium (PT001)

Developed by AstraZeneca

Phase 2/3 in Asthmasmall molecule
Partial signal

NCT03358147 · Phase 2/3 · completed

The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.

Next expected readout: May 2029 · NCT07525375 (registry estimate)

Reported efficacy

Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)

Result source: NCT03358147

Tiotropium bromide

Marketed by Boehringer Ingelheim

Approved in Asthmasmall molecule
Reliable signal

NCT00772538 · Phase 3 · completed

The trial randomized 459 participants to double-blind tiotropium or matching placebo, with 237 receiving tiotropium and 222 placebo. The primary comparisons favored tiotropium, including significant improvements in peak and trough FEV1 at 24 weeks and a significant reduction in time to first severe asthma exacerbation in the pooled twin-trial analysis.

Next expected readout: January 2027 · NCT06679465 (registry estimate)

Reported efficacy

Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Trough FEV1 Response Determined After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Time to First Severe Asthma Exacerbation During the 48-week Treatment of the Pooled Data From the Two Twin Trials 205.416 (NCT00772538) and the Present 205.417 (NCT00776984). (48 weeks): Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026) (met)

Result source: NCT00772538

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGlycopyrronium (PT001)Tiotropium bromide
Severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147
0.1 vs -0.0+0.2 vs placebo2.5 mcg once daily · wk 24 · n 247NCT01172808
40 other results
  • 0.2 vs -0.0 2.5 mcg once daily · wk 24 · n 245 · Phase 3 · primary NCT01172821
  • 0.1 vs 0.1 5 µg/day · wk 24 · n 237 · Phase 3 · primary NCT00772538
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 241 · Phase 3 · primary NCT01172808
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 240 · Phase 3 · primary NCT01172821
  • 0.2 vs 0.0 5 µg/day · wk 24 · n 216 · Phase 3 · primary NCT00776984
  • 0.3 vs 0.2 2.5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 2.5 mcg · wk 24 · n 119 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 2.5 mcg · wk 12 · n 135 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 2.5 μg · wk 12 · n 126 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 2.5 mcg · wk 12 · n 151 · Phase 3 · secondary NCT01316380
  • 0.3 vs 0.3 2.5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.1 vs 0.1 2.5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.3 vs 0.2 5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 5 mcg · wk 24 · n 131 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 5 mcg · wk 12 · n 128 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 5 μg · wk 12 · n 130 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 5 mcg · wk 12 · n 152 · Phase 3 · secondary NCT01316380
  • 0.1 vs 0.1 5 µg/day · wk 48 · n 237 · Phase 3 · secondary NCT00772538
  • 0.4 vs 0.3 5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.2 vs 0.1 5 µg/day · wk 48 · n 216 · Phase 3 · secondary NCT00776984
  • 0.2 vs 0.1 5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.2 vs -0.0 1800 μg · wk 0.21 · n 31 · Phase 1 · primary NCT02573155
  • 0.1 vs -0.0 400 μg · wk 0.21 · n 34 · Phase 1 · primary NCT02573155
  • 0.5 vs -0.0 2100 μg · wk 0.21 · n 5 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 1800 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 900 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 400 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 200 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • -0.0 vs -0.0 50 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs 0.1 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 2.5 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01122680
  • 0.2 vs 0.1 5 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 5 µg once daily · wk 4 · n 143 · Phase 2 · secondary NCT01233284
  • 0.3 vs 0.1 5 µg once daily · wk 4 · n 90 · Phase 2 · secondary NCT01152450
  • 0.4 vs 0.3 5 mcg · wk 4 · n 77 · Phase 2 · secondary NCT01122680
  • 0.3 vs 0.1 2.5 µg twice daily · wk 4 · n 89 · Phase 2 · secondary NCT01152450
  • 0.2 vs 0.1 1.25 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 1.25 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 1.25 mcg · wk 4 · n 73 · Phase 2 · secondary NCT01122680
ACQ-5, change-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147
—Not reported
OCS dose reduction—Not reported—Not reported

Severe exacerbations, annualised rate

Glycopyrronium (PT001)
—Not reported
Tiotropium bromide
—Not reported

Trough FEV1, change

Glycopyrronium (PT001)
0.1 vs 0.1±0 vs placebo28.8 μg · wk 24 · n 196NCT03358147
2 other results
  • 0.1 vs 0.1 14.4 μg · wk 24 · n 199 · Phase 2/3 · secondary NCT03358147
  • 0.1 vs 0.1 7.2 μg · wk 24 · n 205 · Phase 2/3 · secondary NCT03358147
Tiotropium bromide
0.1 vs -0.0+0.2 vs placebo2.5 mcg once daily · wk 24 · n 247NCT01172808
40 other results
  • 0.2 vs -0.0 2.5 mcg once daily · wk 24 · n 245 · Phase 3 · primary NCT01172821
  • 0.1 vs 0.1 5 µg/day · wk 24 · n 237 · Phase 3 · primary NCT00772538
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 241 · Phase 3 · primary NCT01172808
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 240 · Phase 3 · primary NCT01172821
  • 0.2 vs 0.0 5 µg/day · wk 24 · n 216 · Phase 3 · primary NCT00776984
  • 0.3 vs 0.2 2.5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 2.5 mcg · wk 24 · n 119 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 2.5 mcg · wk 12 · n 135 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 2.5 μg · wk 12 · n 126 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 2.5 mcg · wk 12 · n 151 · Phase 3 · secondary NCT01316380
  • 0.3 vs 0.3 2.5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.1 vs 0.1 2.5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.3 vs 0.2 5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 5 mcg · wk 24 · n 131 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 5 mcg · wk 12 · n 128 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 5 μg · wk 12 · n 130 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 5 mcg · wk 12 · n 152 · Phase 3 · secondary NCT01316380
  • 0.1 vs 0.1 5 µg/day · wk 48 · n 237 · Phase 3 · secondary NCT00772538
  • 0.4 vs 0.3 5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.2 vs 0.1 5 µg/day · wk 48 · n 216 · Phase 3 · secondary NCT00776984
  • 0.2 vs 0.1 5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.2 vs -0.0 1800 μg · wk 0.21 · n 31 · Phase 1 · primary NCT02573155
  • 0.1 vs -0.0 400 μg · wk 0.21 · n 34 · Phase 1 · primary NCT02573155
  • 0.5 vs -0.0 2100 μg · wk 0.21 · n 5 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 1800 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 900 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 400 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 200 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • -0.0 vs -0.0 50 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs 0.1 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 2.5 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01122680
  • 0.2 vs 0.1 5 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 5 µg once daily · wk 4 · n 143 · Phase 2 · secondary NCT01233284
  • 0.3 vs 0.1 5 µg once daily · wk 4 · n 90 · Phase 2 · secondary NCT01152450
  • 0.4 vs 0.3 5 mcg · wk 4 · n 77 · Phase 2 · secondary NCT01122680
  • 0.3 vs 0.1 2.5 µg twice daily · wk 4 · n 89 · Phase 2 · secondary NCT01152450
  • 0.2 vs 0.1 1.25 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 1.25 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 1.25 mcg · wk 4 · n 73 · Phase 2 · secondary NCT01122680

ACQ-5, change

Glycopyrronium (PT001)
-0.9 vs -0.9+0.1 vs placebo28.8 μg · wk 24 · n 195NCT03358147
2 other results
  • -0.8 vs -0.9 14.4 μg · wk 24 · n 198 · Phase 2/3 · secondary NCT03358147
  • -1.0 vs -0.9 7.2 μg · wk 24 · n 196 · Phase 2/3 · secondary NCT03358147
Tiotropium bromide
—Not reported

OCS dose reduction

Glycopyrronium (PT001)
—Not reported
Tiotropium bromide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Glycopyrronium (PT001): 5 of 5 rows · Tiotropium bromide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGlycopyrronium (PT001)Tiotropium bromide
Rows use multiple source trials
AQLQ
absolute change · score
0.89 vs 0.96 placebo score @ 24wk28.8 μga,b,c,d,e
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more doses
0.9 vs 0.96 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
1.02 vs 0.96 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.15 vs 0.28 LABA + 1xICS score @ 14wkb,c,d,e
NCT00565266 · Phase 3 · combination · Asthma · phase 3
Dropout rate
14.5%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
16.3%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
14.2%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
11%5 µg/dayf
NCT00772538 · Phase 3
show 39 more results
—
NCT00565266 · Phase 3 · combination · Asthma · phase 3
4.4%2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
3.7%5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.7%2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
3.1%5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
8%2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
4.4%5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.8%2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0%5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
7%2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
7%5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
5%2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
8.7%5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
4.7%2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
5.1%5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
3.2%2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
1.9%5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
9.6%5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
—5 µg QD
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—2.5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—2100 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—900 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—200 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—50 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
1.3%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
3.8%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.9%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.5%5 µg/dayf
NCT00772538 · Phase 3
show 39 more results
—
NCT00565266 · Phase 3 · combination · Asthma · phase 3
—2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
—5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0%2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
1.5%5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0%2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0%5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0%2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0%5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.9%2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
1.8%5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
1.5%2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
3%5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.8%2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.8%5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
1.3%2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.6%5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.9%5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
—5 µg QD
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—2.5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—2100 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—900 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—200 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—50 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
Serious AEs
3.8%28.8 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
2.9%14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
2.5%7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
7.6%5 µg/dayf
NCT00772538 · Phase 3
show 39 more results
1.5%
NCT00565266 · Phase 3 · combination · Asthma · phase 3
2.2%2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.7%5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
1.5%2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
3.1%5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
1.6%2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
2.2%5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.8%2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
1.5%5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
3.5%2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
3.5%5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
1.9%2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
1.5%5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
2.7%2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
2.8%5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0%2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.6%5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
8.7%5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0%5 µg QD
NCT01696071 · Phase 2 · registry result, not featured evidence
1%2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0%5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0%1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0%2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
1.4%5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0%1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0%2.5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
2.2%5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
1.3%5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
1.3%1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0%2100 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%900 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
2.9%400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%200 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%50 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
28.8 μg
upper respiratory tract infection 6% (placebo 8%)
nasopharyngitis 4.7% (placebo 3.4%)
sinusitis 4.3% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
14.4 μg
nasopharyngitis 6.3% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 2.9% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
7.2 μg
nasopharyngitis 7.1% (placebo 3.4%)
upper respiratory tract infection 5.8% (placebo 8%)
sinusitis 1.7% (placebo 1.3%)
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
5 µg/dayf
asthma 34.6% (placebo 44.6%)
peak expiratory flow rate decreased 20.7% (placebo 26.1%)
nasopharyngitis 8% (placebo 9%)
NCT00772538 · Phase 3
show 28 more results
urgent care visit due to asthma 1%
NCT00565266 · Phase 3 · combination · Asthma · phase 3
2.5 mcg
asthma 36.3% (placebo 43.5%)
peak expiratory flow rate decreased 23% (placebo 20.6%)
nasopharyngitis 11.1% (placebo 9.9%)
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
5 mcg
asthma 34.1% (placebo 43.5%)
peak expiratory flow rate decreased 21.5% (placebo 20.6%)
respiratory tract infection 9.6% (placebo 12.2%)
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
2.5 mcg
asthma 14.7% (placebo 21.6%)
peak expiratory flow rate decreased 11% (placebo 14.9%)
nasopharyngitis 4.4% (placebo 8.2%)
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
5 mcg
asthma 16.9% (placebo 21.6%)
peak expiratory flow rate decreased 11.5% (placebo 14.9%)
nasopharyngitis 4.6% (placebo 8.2%)
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
2.5 mcg
asthma 21.6% (placebo 23.2%)
nasopharyngitis 10.4% (placebo 12.3%)
respiratory tract infection viral 8.8% (placebo 8%)
NCT01257230 · Phase 3 · registry result, not featured evidence
5 mcg
asthma 16.4% (placebo 23.2%)
nasopharyngitis 14.9% (placebo 12.3%)
respiratory tract infection viral 7.5% (placebo 8%)
NCT01257230 · Phase 3 · registry result, not featured evidence
2.5 μg
asthma 11% (placebo 10.4%)
peak expiratory flow rate decreased 7.1% (placebo 9.6%)
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
5 μg
asthma 10.8% (placebo 10.4%)
peak expiratory flow rate decreased 3.8% (placebo 9.6%)
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
2.5 µg once daily
nasopharyngitis 44.7% (placebo 42.1%)
asthma 29.8% (placebo 36.8%)
bronchitis 13.2% (placebo 7%)
NCT01340209 · Phase 3 · registry result, not featured evidence
5 µg once daily
nasopharyngitis 48.2% (placebo 42.1%)
asthma 28.1% (placebo 36.8%)
peak expiratory flow rate decreased 15.8% (placebo 21.1%)
NCT01340209 · Phase 3 · registry result, not featured evidence
2.5 mcg once daily
asthma 13.7% (placebo 21.6%)
peak expiratory flow rate decreased 10.7% (placebo 19%)
nasopharyngitis 6.9% (placebo 8.2%)
NCT01172808 · Phase 3 · registry result, not featured evidence
5 mcg once daily
asthma 22.7% (placebo 21.6%)
peak expiratory flow rate decreased 12.9% (placebo 19%)
nasopharyngitis 8.3% (placebo 8.2%)
NCT01172808 · Phase 3 · registry result, not featured evidence
2.5 mcg once daily
asthma 17.1% (placebo 21.3%)
nasopharyngitis 12.1% (placebo 10.2%)
peak expiratory flow rate decreased 8.2% (placebo 11%)
NCT01172821 · Phase 3 · registry result, not featured evidence
5 mcg once daily
asthma 19.8% (placebo 21.3%)
peak expiratory flow rate decreased 9.9% (placebo 11%)
nasopharyngitis 7.5% (placebo 10.2%)
NCT01172821 · Phase 3 · registry result, not featured evidence
2.5 mcg
asthma 15.6% (placebo 12.3%)
peak expiratory flow rate decreased 5.8% (placebo 3.9%)
NCT01316380 · Phase 3 · registry result, not featured evidence
5 mcg
asthma 11% (placebo 12.3%)
peak expiratory flow rate decreased 3.9% (placebo 3.9%)
NCT01316380 · Phase 3 · registry result, not featured evidence
5 µg/day
asthma 37.9% (placebo 47.9%)
peak expiratory flow rate decreased 20.1% (placebo 27.4%)
nasopharyngitis 14.6% (placebo 15.4%)
NCT00776984 · Phase 3 · registry result, not featured evidence
2.5 µg once daily
headache 7.8% (placebo 4.3%)
NCT01152450 · Phase 2 · registry result, not featured evidence
5 µg once daily
headache 5.6% (placebo 4.3%)
NCT01152450 · Phase 2 · registry result, not featured evidence
2100 μg
nasopharyngitis 40% (placebo 8.3%)
bronchitis viral 20% (placebo 0%)
feeling hot 20% (placebo 8.3%)
NCT02573155 · Phase 1 · registry result, not featured evidence
1800 μg
headache 16.7% (placebo 25%)
nausea 16.7% (placebo 0%)
neck pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
1800 μg
headache 9.7% (placebo 25%)
chronic obstructive pulmonary disorder 3.2% (placebo 0%)
nasopharyngitis 3.2% (placebo 8.3%)
NCT02573155 · Phase 1 · registry result, not featured evidence
900 μg
headache 33.3% (placebo 25%)
back pain 16.7% (placebo 0%)
cough 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
400 μg
headache 33.3% (placebo 25%)
back pain 16.7% (placebo 0%)
neck pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
400 μg
headache 14.7% (placebo 25%)
chronic obstructive pulmonary disorder 5.9% (placebo 0%)
nasopharyngitis 2.9% (placebo 8.3%)
NCT02573155 · Phase 1 · registry result, not featured evidence
200 μg
abscess oral 16.7% (placebo 0%)
chest discomfort 16.7% (placebo 8.3%)
chest pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
50 μg
headache 50% (placebo 25%)
nasopharyngitis 50% (placebo 8.3%)
back pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 3 versus Phase 2/3.
  3. cPopulation context differs: baseline_threshold differs (fev1_pct_predicted>40 versus fev1_pct_predicted<85, fev1_pct_predicted>40); prior_therapy differs (none recorded versus experienced).
  4. dTreatment context has not been resolved for both arms.
  5. eAssessment timepoints differ: 14 weeks versus 24 weeks.
  6. fPopulation comparability has not been reviewed for 39 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Glycopyrronium (PT001)

FEV1 AUC0-4 0.294 vs 0.24 placebo L @ 24wk28.8 μg
absolute change · L
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.284 vs 0.24 placebo L @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.308 vs 0.24 placebo L @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
Moderate to Severe Exacerbation Rate Annualized 0.43 vs 0.55 placebo per year @ 24wk28.8 μg
event rate · per year
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
0.44 vs 0.55 placebo per year @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
0.41 vs 0.55 placebo per year @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
ACQ-7 -0.78 vs -0.8 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
-0.73 vs -0.8 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-0.9 vs -0.8 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
ACQ-5 -0.87 vs -0.93 placebo score @ 24wk28.8 μg
absolute change · score
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
show 2 more results
-0.8 vs -0.93 placebo score @ 24wk14.4 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3
-1.02 vs -0.93 placebo score @ 24wk7.2 μg
NCT03358147 · Phase 2/3 · Asthma · phase 2/3

Tiotropium bromide

FEV1 Peak 0.395 vs 0.225 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 30 more results
0.474 vs 0.351 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.287 vs 0.252 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.507 vs 0.373 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.55 vs 0.438 placebo L @ 12wk2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.289 vs 0.053 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.287 vs 0.075 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.293 vs 0.134 placebo L @ 12wk2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.29 vs 0.185 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.244 vs 0.116 placebo L2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.546 vs 0.489 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.401 vs 0.315 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.367 vs 0.295 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.389 vs 0.225 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.477 vs 0.351 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.391 vs 0.252 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.547 vs 0.373 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.528 vs 0.438 placebo L @ 12wk5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.25 vs 0.053 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.244 vs 0.075 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.262 vs 0.134 placebo L @ 12wk5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.401 vs 0.248 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.397 vs 0.245 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.272 vs 0.185 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.304 vs 0.116 placebo L5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.468 vs 0.337 placebo L @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.602 vs 0.489 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.469 vs 0.337 placebo L @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.261 vs 0.185 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.255 vs 0.116 placebo L1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.556 vs 0.489 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
Time to First Severe Exacerbation NA vs NA placebo months @ 24wk2.5 mcg once daily
time to event · months
NCT01172808 · Phase 3 · registry result, not featured evidence
show 7 more results
NA vs NA placebo months2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months @ 48wk5 µg/day
NCT00772538 · Phase 3
NA vs NA placebo months @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
FVC Peak 0.325 vs 0.215 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 30 more results
0.43 vs 0.361 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.201 vs 0.244 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.419 vs 0.331 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.37 vs 0.279 placebo L @ 12wk2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.219 vs 0.045 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.181 vs 0.071 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.231 vs 0.126 placebo L @ 12wk2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.253 vs 0.202 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.163 vs 0.092 placebo L2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.554 vs 0.546 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.445 vs 0.355 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.462 vs 0.337 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.307 vs 0.215 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.413 vs 0.361 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.275 vs 0.244 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.403 vs 0.331 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.342 vs 0.279 placebo L @ 12wk5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.148 vs 0.045 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.16 vs 0.071 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.183 vs 0.126 placebo L @ 12wk5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.416 vs 0.323 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.42 vs 0.305 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.239 vs 0.202 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.229 vs 0.092 placebo L5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.35 vs 0.302 placebo L @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.548 vs 0.546 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.38 vs 0.302 placebo L @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.208 vs 0.202 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.171 vs 0.092 placebo L1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.554 vs 0.546 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
FVC Trough 0.246 vs 0.154 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 28 more results
0.341 vs 0.28 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.094 vs 0.141 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.345 vs 0.281 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.085 vs 0.122 placebo L @ 52wk2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
0.086 vs -0.039 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.039 vs -0.048 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.107 vs 0.06 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.076 vs 0.004 placebo L @ 4wk2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.381 vs 0.357 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.157 vs 0.022 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.173 vs 0.062 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.206 vs 0.154 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.333 vs 0.28 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.15 vs 0.141 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.316 vs 0.281 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.204 vs 0.122 placebo L @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
0.036 vs -0.039 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.035 vs -0.048 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.15 vs 0.044 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.142 vs 0.072 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.113 vs 0.06 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.102 vs 0.004 placebo L @ 4wk5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.168 vs 0.112 placebo L @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.4 vs 0.357 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.179 vs 0.112 placebo L @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.109 vs 0.06 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.058 vs 0.004 placebo L @ 4wk1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.375 vs 0.357 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
FEV1 AUC0-3 0.192 vs -0.033 placebo L @ 24wk2.5 mcg once daily
absolute change · L
NCT01172808 · Phase 3 · registry result, not featured evidence
show 5 more results
0.315 vs 0.229 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.289 vs 0.217 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.163 vs -0.033 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.307 vs 0.164 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.31 vs 0.172 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
FVC AUC(0-3 0.105 vs 0.145 placebo L @ 12wk2.5 mcg
absolute change · L
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
show 22 more results
0.33 vs 0.24 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.262 vs 0.175 placebo L @ 12wk2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.092 vs -0.066 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.101 vs 0 placebo L @ 12wk2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.134 vs 0.087 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.047 vs -0.028 placebo L2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.417 vs 0.413 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.328 vs 0.23 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.344 vs 0.223 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.182 vs 0.145 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.311 vs 0.24 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.227 vs 0.175 placebo L @ 12wk5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.041 vs -0.066 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.061 vs 0 placebo L @ 12wk5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.295 vs 0.187 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.299 vs 0.19 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.11 vs 0.087 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.11 vs -0.028 placebo L5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.429 vs 0.413 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.097 vs 0.087 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.036 vs -0.028 placebo L1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.441 vs 0.413 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
Morning PEF 10.934 vs 2.288 placebo L/min @ 52wk2.5 µg once daily
absolute change · L/min
NCT01340209 · Phase 3 · registry result, not featured evidence
show 5 more results
15.297 vs -6.996 placebo L/min @ 24wk5 µg/day
NCT00772538 · Phase 3
8.504 vs 2.288 placebo L/min @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
17.396 vs -3.258 placebo L/min @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
24.31 vs 1.953 placebo L/min @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
23.281 vs 1.953 placebo L/min @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
Evening PEF 1.101 vs -10.357 placebo L/min @ 52wk2.5 µg once daily
absolute change · L/min
NCT01340209 · Phase 3 · registry result, not featured evidence
show 5 more results
19.402 vs -3.865 placebo L/min @ 24wk5 µg/day
NCT00772538 · Phase 3
6.041 vs -10.357 placebo L/min @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
25.158 vs -7.295 placebo L/min @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
27.096 vs -1.56 placebo L/min @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
28.36 vs -1.56 placebo L/min @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
FEV1 Morning 0.209 vs 0.191 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 11 more results
0.259 vs 0.236 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.142 vs 0.174 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.101 vs 0.021 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.099 vs 0.02 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.062 vs -0.055 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.126 vs 0.191 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.221 vs 0.236 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.125 vs 0.174 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.073 vs 0.021 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.084 vs 0.02 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.096 vs 0.006 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
FEV1 Evening 0.142 vs 0.167 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 11 more results
0.208 vs 0.202 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.104 vs 0.155 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.065 vs 0 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.066 vs -0.002 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.075 vs -0.05 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.092 vs 0.167 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.159 vs 0.202 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.094 vs 0.155 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.039 vs 0 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.064 vs -0.002 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.122 vs -0.015 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
PEF Variability -0.942% (n=135) vs -1.204% (n=131) placebo @ 24wk2.5 mcg
absolute change · percentage points
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 18 more results
-0.048% (n=135) vs -0.32% (n=131) placebo @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
-0.8% (n=136) vs 0.15% (n=127) placebo @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
-0.968% (n=114) vs -0.367% (n=56) placebo @ 52wk2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
-1.958% (n=244) vs -1.4% (n=237) placebo @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
-1.401% (n=237) vs -0.448% (n=232) placebo @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
-0.711% (n=146) vs -0.171% (n=142) placebo @ 4wk2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
-0.714% (n=237) vs -0.997% (n=222) placebo @ 24wk5 µg/day
NCT00772538 · Phase 3
-1.038% (n=135) vs -1.204% (n=131) placebo @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
-0.899% (n=135) vs -0.32% (n=131) placebo @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
-0.352% (n=125) vs 0.15% (n=127) placebo @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.197% (n=114) vs -0.367% (n=56) placebo @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
0.18% (n=234) vs -1.4% (n=237) placebo @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
-0.627% (n=234) vs -0.448% (n=232) placebo @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
-0.611% (n=216) vs -1.808% (n=232) placebo @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
-0.248% (n=144) vs -0.171% (n=142) placebo @ 4wk5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.685% (n=88) vs 0.296% (n=91) placebo @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.619% (n=89) vs 0.296% (n=91) placebo @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
-0.285% (n=146) vs -0.171% (n=142) placebo @ 4wk1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
Asthma Exacerbation Free 51.1% (n=237) vs 38.3% (n=222) placebo @ 48wk5 µg/day
responder rate · % of participants
0 exacerbations
NCT00772538 · Phase 3 · converted to % from 121 Participants as posted

+ 72 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrronium (PT001)'s landscape · Tiotropium bromide's landscape